journal
MENU ▼
Read by QxMD icon Read
search

Critical Reviews in Oncology/hematology

journal
https://www.readbyqxmd.com/read/29055771/erratum-to-systematic-literature-review-of-health-related-quality-of-life-in-locally-advanced-non-small-cell-lung-cancer-has-it-yet-become-state-of-the-art-crit-rev-oncol-hematol-119-november-2017-40-49
#1
Lotte van der Weijst, Veerle Surmont, Wim Schrauwen, Yolande Lievens
No abstract text is available yet for this article.
October 19, 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29110971/the-effects-of-enzalutamide-and-abiraterone-on-skeletal-related-events-and-bone-radiological-progression-free-survival-in-castration-resistant-prostate-cancer-patients-an-indirect-comparison-of-randomized-controlled-trials
#2
REVIEW
Sergio Rizzo, Antonio Galvano, Francesco Pantano, Michele Iuliani, Bruno Vincenzi, Francesco Passiglia, Silvia Spoto, Giuseppe Tonini, Viviana Bazan, Antonio Russo, Daniele Santini
Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist enzalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients, using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents on two prostate-specific endpoints as radiographic progression-free survival (rPFS) and time to first skeletal-related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and enzalutamide...
October 16, 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29032892/evaluation-and-management-of-skeletal-disease-in-cancer-care
#3
REVIEW
Anuhya Kommalapati, Sri Harsha Tella, Mary Angelynne Esquivel, Ricardo Correa
Recently, there have been considerable advancements in cancer therapies thereby prolonging the life of cancer survivors. However, these recent advancements present new challenges in the management of bone disease in cancer survivors. Bone acts as a fertile soil for cancer seeding and bone health is often compromised because of increased inflammatory cytokines in cancer, direct cancer metastasis and toxic effects of anti-cancer therapies. This effect is more pronounced in elderly population who already have compromised bone mineral density leading to increased skeletal related events and bone pain...
September 8, 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28927785/do-alcoholic-beverages-obesity-and-other-nutritional-factors-modify-the-risk-of-familial-colorectal-cancer-a-systematic-review
#4
REVIEW
Anthony Fardet, Nathalie Druesne-Pecollo, Mathilde Touvier, Paule Latino-Martel
PURPOSE: Individuals with family history of colorectal cancer are at higher risk of colorectal cancer than the general population. Until now, guidelines for familial colorectal cancer risk have only pointed at early diagnosis efforts via screening tests and surveillance, and payed scarce or no attention to lowering exposure to modifiable risk factors, notably nutritional factors. METHODS: We conducted a systematic review of epidemiological studies investigating the associations between nutritional factors, family history of colorectal cancer, and colorectal cancer risk...
September 7, 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28916378/clinical-pharmacology-of-anti-angiogenic-drugs-in-oncology
#5
REVIEW
P Gougis, J Wassermann, J P Spano, N Keynan, C Funck-Brentano, J E Salem
Abnormal vasculature proliferation is one of the so-called hallmarks of cancer. Angiogenesis inhibitor therapies are one of the major breakthroughs in cancer treatment in the last two decades. Two types of anti-angiogenics have been approved: monoclonal antibodies and derivatives, which are injected and target the extracellular part of a receptor, and protein kinase inhibitors, which are orally taken small molecules targeting the intra-cellular Adenosine Triphosphate -pocket of different kinases. They have become an important part of some tumors' treatment, both in monotherapy or in combination...
September 1, 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28893462/developing-drugs-in-cancer-related-bone-pain
#6
REVIEW
Maurizio Lucchesi, Gaetano Lanzetta, Andrea Antonuzzo, Antonio Rozzi, Iacopo Sardi, Claudio Favre, Carla Ida Ripamonti, Daniele Santini, Grazia Armento
INTRODUCTION: Cancer-related bone pain is a frequent and important key problem for metastatic patients that may reduce quality of life, with related limitations in daily activities and morbidity. Often traditional approach to pain may fail given the complex pathophysiology of this phenomenon. METHODS: The aim of this review is to describe promising therapies for cancer-related bone pain, from the pathophysiology to the clinical trials currently ongoing. Moreover, any new evidence for better approach to cancer-related bone pain with the traditional drugs is also considered...
August 25, 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29065986/critical-risk-benefit-assessment-of-the-novel-anti-cancer-aurora-a-kinase-inhibitor-alisertib-mln8237-a-comprehensive-review-of-the-clinical-data
#7
REVIEW
Yaman Tayyar, Luqman Jubair, Sora Fallaha, Nigel A J McMillan
BACKGROUND: Many current anticancer chemotherapeutics suffer from significant side effects, which have led to the exploration of more targeted therapies. This resulted in the exploration of inhibitors of Aurora A kinase as a potential anti-cancer treatment. Alisertib (MLN8237) has proven to be a potent Aurora A kinase inhibitor that had the highest safety profile among its therapeutic family. Phase I/II/III clinical trials with Alisertib have been carried out and reported promising efficacy, yet serious side effects...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29065985/hand-foot-skin-reaction-with-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitors-in-cancer-patients-a-systematic-review-and-meta-analysis
#8
REVIEW
Jing Li, Jian Gu
A meta-analysis was conducted to systematically review the risk of hand-foot skin reaction (HFSR) with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in patients with cancer. The relevant studies of the randomized controlled trials (RCTs) in cancer patients treated with VEGFR-TKIs were retrieved and the systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published till May 2017. Twenty-one RCTs and 9552 patients were included. The current analysis suggested that the use of VEGFR-TKIs increased the risk of all-grade HFSR (7...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29065984/systematic-literature-review-of-health-related-quality-of-life-in-locally-advanced-non-small-cell-lung-cancer-has-it-yet-become-state-of-the-art
#9
REVIEW
Lotte van der Weijst, Veerle Surmont, Wim Schrauwen, Yolande Lievens
Lung cancer and its treatment have an important impact on the patients' health-related quality-of-life (HRQoL). A systematic literature review of prospective clinical studies published since 2005 and measuring HRQoL in patients with locally-advanced non-small cell lung cancer (LA- NSCLC) was performed. Besides reviewing the HRQoL impact of LA-NSCLC treatment, it critically examined the frequency, methodology and quality of HRQoL data collection and analysis in LA-NSCLC clinical studies. Out of 814 potentially eligible publications, only 27 (representing 19 individual studies) met the inclusion criteria...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29065983/combination-immunotherapy-strategies-in-advanced-non-small-cell-lung-cancer-nsclc-does-biological-rationale-meet-clinical-needs
#10
REVIEW
Ilaria Attili, Antonio Passaro, Alberto Pavan, PierFranco Conte, Filippo De Marinis, Laura Bonanno
Immune checkpoint inhibitors (ICIs) have emerged as one of the main new therapeutic options for advanced non-small cell lung cancer (NSCLC) patients. Even though they demonstrated superiority towards standard chemotherapy in different disease settings, the response rates do not exceed 45% in highly molecularly selected patients. This is related to known limitations of the available biomarkers, as well to the complex and dynamic nature of tumor microenvironment. The study of the different strategies adopted by tumor cells to escape the immune system lays the basis of the new combination strategies...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29065982/corrigendum-to-the-vicious-circle-of-treatment-induced-toxicities-in-locally-advanced-head-and-neck-cancer-and-the-impact-on-treatment-intensity-crit-rev-oncol-hematol-116-2017-82-88
#11
Paolo Bossi, Maria Cossu Rocca, Renzo Corvò, Roberta Depenni, Vittorio Guardamagna, Franco Marinangeli, Francesco Miccichè, Fabio Trippa
No abstract text is available yet for this article.
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29065981/complexity-of-the-genomic-landscape-of-renal-cell-carcinoma-implications-for-targeted-therapy-and-precision-immuno-oncology
#12
REVIEW
Joseph M Sanfrancesco, Liang Cheng
The topic of tumoral heterogeneity at the genetic level has become relevant in various solid origin tumors, particularly in an age of targeted treatment. Renal cell carcinoma is known for a sizable subset of tumors presenting at advanced clinical stage, further highlighting the importance and timeliness of this topic and its potential impact on adjuvant therapy. Recent studies have shown that molecular aberrations in renal cell carcinoma go beyond known truncal mutations and that downstream, subclonal aberrations are spatially heterogenous...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29065980/genistein-its-role-in-metabolic-diseases-and-cancer
#13
REVIEW
Vidya Mukund, Dhruv Mukund, Vinay Sharma, Mastan Mannarapu, Afroz Alam
Genistein is an isoflavone present in soy and is known to have multiple molecular effects, such as the inhibition of inflammation, promotion of apoptosis, and modulation of steroidal hormone receptors and metabolic pathways. Since these molecular effects impact carcinogenesis, cancer propagation, obesity, osteoporosis, and metabolic syndromes, genistein plays an important role in preventing and treating common disorders. The role of genistein has not been adequately evaluated in all these clinical settings...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29065979/not-all-immune-checkpoint-inhibitors-are-created-equal-meta-analysis-and-systematic-review-of-immune-related-adverse-events-in-cancer-trials
#14
REVIEW
B El Osta, F Hu, R Sadek, R Chintalapally, S-C Tang
BACKGROUND: Targeting immune checkpoints is a novel approach in cancer therapy. This strategy may trigger immune related adverse events (irAE). We hypothesize that the incidence of irAE will be greater in patients receiving immune checkpoint inhibitors (ICI) targeting only immune cells compared to those that also target tumor cells (PD-L1). In addition, we compared the specific irAE profile and overall response rate (ORR) for each ICI by target(s). MATERIALS AND METHODS: We reviewed all ICI cancer clinical trials (90; 174 arms) that reported irAE and were published through MEDLINE...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29042085/advances-in-the-management-of-her2-positive-early-breast-cancer
#15
REVIEW
José Baselga, Robert E Coleman, Javier Cortés, Wolfgang Janni
While trastuzumab is firmly established as the cornerstone of therapy for both early and advanced breast cancer expressing human epidermal growth factor receptor 2 (HER2), many patients either do not respond to trastuzumab treatment or progress following therapy. Improved understanding of breast cancer biology, particularly the complex signaling interactions managed by the HER family of receptors, have resulted in development of several novel HER2-directed therapies and combinations. This article will review the novel approaches to HER2 targeting that have been developed in recent years, with particular focus on results from these approaches in early breast cancer, and will discuss strategies to improve the tolerability of HER2-directed therapies, including prevention of cardiac toxicity and diarrhea...
November 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28917273/mechanisms-and-risk-factors-of-thrombosis-in-cancer
#16
REVIEW
Anna Falanga, Laura Russo, Viola Milesi, Alfonso Vignoli
The close relationship between cancer and thrombosis is known since more than a century. Venous thromboembolism (VTE) may be the first manifestation of an occult malignancy in an otherwise healthy individual. Cancer patients commonly present with abnormalities of laboratory coagulation tests, indicating an ongoing subclinical hypercoagulable condition. The results of laboratory tests demonstrate that a process of fibrin formation and removal parallels the development of malignancy, which is of particular interest since fibrin and other clotting products are important for both thrombogenesis and tumor progression...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28917272/towards-personalized-medicine-of-colorectal-cancer
#17
REVIEW
Mohammad Azhar Aziz, Zeyad Yousef, Ayman M Saleh, Sameer Mohammad, Bandar Al Knawy
Efforts in colorectal cancer (CRC) research aim to improve early detection and treatment for metastatic stages which could translate into better prognosis of this disease. One of the major challenges that hinder these efforts is the heterogeneous nature of CRC and involvement of diverse molecular pathways. New large-scale 'omics' technologies are making it possible to generate, analyze and interpret biological data from molecular determinants of CRC. The developments of sophisticated computational analyses would allow information from different omics platforms to be integrated, thus providing new insights into the biology of CRC...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28917271/cognitive-impairment-and-chemotherapy-a-brief-overview
#18
REVIEW
Milena Vitali, Carla Ida Ripamonti, Fausto Roila, Claudia Proto, Diego Signorelli, Martina Imbimbo, Giulia Corrao, Angela Brissa, Gallucci Rosaria, Filippo de Braud, Marina Chiara Garassino, Giuseppe Lo Russo
Patients with cancer are experiencing long-term survival following chemotherapy, but the treatment may also be associated with short and long-term toxicity, including the possibility of cognitive dysfunction. A literature overview indicated a significant association between chemotherapy and cognitive impairment but prospective longitudinal research is warranted to examine the degree and persisting nature of this decline. Although chemotherapeutic agents are unlikely to cross the blood-brain barrier, it has been alleged that the occurrence of neurotoxicity is linked to the pro-inflammatory cytokine pathways...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28917270/cancer-related-fatigue-in-adolescents-and-young-adults-a-systematic-review-of-the-literature
#19
REVIEW
E Nowe, Y Stöbel-Richter, A Sender, K Leuteritz, M Friedrich, K Geue
Adolescents and young adults with cancer (AYA) represent a specific age cohort dealing with the disease in a stage of life characterized by development, upheavals, and establishment. The aim of this study was to point out the state of research on how AYA are affected by cancer-related fatigue (CRF). RESULTS: Twelve articles were included. CRF was found to be higher in AYA than in either of the comparison groups, healthy peers and older cancer patients. Most included studies did not measure CRF with multidimensional, fatigue-specific instruments...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28917269/triplet-folfoxiri-versus-doublet-folfox-or-folfiri-backbone-chemotherapy-as-first-line-treatment-of-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis
#20
REVIEW
Rui Pedro Marques, Gonçalo S Duarte, Carmelo Sterrantino, Helena Luna Pais, António Quintela, Ana Paula Martins, João Costa
Uncertainty exists regarding the comparative effectiveness of triplet chemotherapy (FOLFOXIRI) as backbone first-line chemotherapy for metastatic colorectal cancer (mCRC). We conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs) comparing triplet versus doublet chemotherapy (FOLFOX or FOLFIRI) as first-line therapy in mCRC. Methods and reporting followed PRISMA and SAMPL guidelines. Eight RCTs were included, comprising 1732 patients. In pooled analysis, FOLFOXIRI was associated with improvements in efficacy outcomes, notably with a 25% survival increase (95%CI: 10-37%)...
October 2017: Critical Reviews in Oncology/hematology
journal
journal
20089
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"